SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2026)
SAB Biotherapeutics (SABS) reported Enterprise Value of -$107.4 million for Q1 2026, down 735.71% on a YoY basis from $16.9 million in Q1 2025, and down 11.18% quarter-over-quarter from -$96.6 million in Q4 2025.
SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Enterprise Value for 7 years, with the latest figure at -$107.4 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 735.71% year-over-year to -$107.4 million; the trailing twelve-month figure through Mar 2026 stood at -$107.4 million (down 735.71% YoY), and the FY2025 full-year result was -$96.6 million, down 365.27% from the prior year.
- Enterprise Value for Q1 2026 stood at -$107.4 million, down from -$96.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$2.4 million in Q3 2023, with the low at -$110.9 million in Q3 2025.
- Historically, Enterprise Value has averaged -$35.8 million across 5 years, with a median of -$20.8 million in 2024.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 1153.36% — and 2025, when it surged 84.66%.
- SAB Biotherapeutics' Enterprise Value stood at -$15.0 million in 2022, then plunged by 275.93% to -$56.6 million in 2023, then surged by 63.3% to -$20.8 million in 2024, then sank by 365.27% to -$96.6 million in 2025, then fell by 11.18% to -$107.4 million in 2026.
- The last three Enterprise Value figures came in at -$107.4 million (Q1 2026), -$96.6 million (Q4 2025), and -$110.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -107.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.39 Mn |
| Dec 31, 2025 | -96.59 Mn |
| Sep 30, 2025 | -110.88 Mn |
| Jun 30, 2025 | -5.71 Mn |
| Mar 31, 2025 | -12.85 Mn |
| Dec 31, 2024 | -20.76 Mn |
| Sep 30, 2024 | -30.40 Mn |
| Jun 30, 2024 | -37.24 Mn |
| Mar 31, 2024 | -44.06 Mn |
| Dec 31, 2023 | -56.57 Mn |
| Sep 30, 2023 | -2.43 Mn |
| Jun 30, 2023 | -7.77 Mn |
| Mar 31, 2023 | -13.06 Mn |
| Dec 31, 2022 | -15.05 Mn |
| Sep 30, 2022 | -8.33 Mn |
| Jun 30, 2022 | -16.62 Mn |
| Mar 31, 2022 | -22.41 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -10.75 Mn |
| Jun 30, 2021 | -10.23 Mn |